Elicio Therapeutics Q3 net loss $10.7M; ELI-002 RFS 16.3 months, Phase 2 planned early 2024

Elicio Therapeutics, Inc.

2023-Q3 EPS reported -$3.19

Net loss of $10.7M ($1.27/sh) vs $7.2M loss ($22.67/sh) in Q3 2022; cash $14.1M vs $6.2M year-end 2022.
ELI-002 2P showed median relapse-free survival of 16.3 months; T-cell response correlated with 86% risk reduction (HR 0.14, p=0.013).
ELI-002 7P Phase 2 monotherapy trial in adjuvant PDAC to start early 2024; interim analysis expected Q1 2025.
R&D expense $7.3M (+58% YoY) and G&A $3.5M (+198% YoY) driven by public company costs and trial expansion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Elicio Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-23-000077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.